Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Enanta Pharma (ENTA) Tops Q3 EPS by 17c
August 6, 2019 4:01 PM EDTEnanta Pharma (NASDAQ: ENTA) reported Q3 EPS of $0.33, $0.17 better than the analyst estimate of $0.16. Revenue for the quarter came in at $44.4 million versus the consensus estimate of $49.98 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More